- Published on
KembaraXtra-Emergency and Acute Medicine - Organophosphate Poisoning
Description: Organophosphate poisoning results from irreversible inhibition of cholinesterase enzymes, particularly acetylcholinesterase, leading to accumulation of acetylcholine at central and peripheral synapses and subsequent cholinergic overdrive. Toxic effects involve muscarinic, nicotinic, and central nervous system pathways, which may overlap in presentation. Mortality is primarily due to respiratory failure caused by bronchorrhea, bronchoconstriction, respiratory muscle weakness, and central respiratory depression. In children, symptoms may be difficult to distinguish, and seizures occur more frequently than in adults.
Etiology: Exposure commonly occurs through agricultural insecticides or chemical nerve agents such as sarin, soman, tabun, and VX. These agents are rapidly absorbed through the lungs, gastrointestinal tract, skin, mucous membranes, and eyes, making even dermal exposure potentially life-threatening.
Clinical features: The classic presentation is the cholinergic toxidrome characterized by DUMBELS: diarrhea and diaphoresis, urination, miosis and muscle fasciculations, bradycardia with bronchorrhea and bronchospasm, emesis, lacrimation, and salivation. Mild exposure causes headache, dizziness, weakness, tremors, and anorexia. Moderate exposure leads to muscle fasciculations progressing to flaccid paralysis, respiratory muscle weakness, agitation, confusion, pinpoint pupils, nausea, vomiting, and excessive secretions. Severe exposure presents with seizures, coma, centrally mediated respiratory depression, bronchoconstriction, cyanosis, cardiac conduction abnormalities, profuse secretions, and urinary or fecal incontinence.
Evaluation: A focused history should assess occupational exposure, recent insecticide use, possible suicide attempt, and access to pesticides, with retrieval of the original container if available. Physical examination emphasizes identification of parasympathetic signs, muscle weakness, and respiratory compromise. Diagnosis is clinical, and treatment should not be delayed for laboratory confirmation.
Diagnostic testing: Red blood cell cholinesterase levels best reflect synaptic inhibition but are often delayed, while plasma cholinesterase levels are more rapidly available but less specific. Severity correlates with the degree of enzyme inhibition, though therapy must begin immediately regardless of results. Additional testing includes CBC, electrolytes, renal function, glucose, arterial blood gas when respiratory symptoms are present, ECG for dysrhythmias or heart block, and chest radiography if pulmonary edema or aspiration is suspected.
Management: Initial management prioritizes decontamination and protection of healthcare workers using appropriate personal protective equipment. All contaminated clothing should be removed and double-bagged, and skin thoroughly washed with soap and water. Airway protection, oxygenation, and ventilatory support are critical, with early intubation when indicated. Atropine is the primary antidote for muscarinic symptoms and should be administered in escalating doses every five minutes until bronchial secretions are dry, without using pupil size or heart rate as treatment endpoints. Pralidoxime should be given early to reverse nicotinic effects and regenerate cholinesterase before enzyme aging occurs, improving muscle strength and reducing paralysis. Supportive care includes frequent suctioning, avoidance of succinylcholine during intubation, and cautious gastric decontamination in early severe ingestions.
Disposition and follow-up: Any symptomatic patient or those requiring atropine should be admitted, typically to an intensive care setting, for close monitoring. Asymptomatic patients may be discharged after 6–12 hours of observation with clear return precautions and reliable follow-up. Intentional exposures require psychiatric evaluation, and poison control or toxicology consultation is recommended for significant or ongoing symptoms.
Key points: Inadequate atropine dosing is the most common cause of treatment failure. Clinical diagnosis should guide therapy without delay for laboratory confirmation. Recognition and aggressive management of respiratory compromise are essential to reduce mortality.
0 Comments
